Clinical Trial Update: Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of sorafenib and temsirolimus for metastatic, recurrent, or unresectable melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Nexavar (Sorafenib)
• Torisel (Temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Recurrent Melanoma | Phase 2 | Status: WITHDRAWN